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Initially identified as monomers, G protein-coupled receptors (GPCRs) can also form
functional homo- and heterodimers that act as distinct signaling hubs for cellular signal
integration. We previously found that the angiotensin II (Ang II) type 1 receptor (AT1R)
and the prostaglandin F2α (PGF2α) receptor (FP), both important in the control of
smooth muscle contractility, form such a functional heterodimeric complex in HEK
293 and vascular smooth muscle cells. Here, we hypothesize that both Ang II- and
PGF2α-induced activation of the AT1R/FP dimer, or the parent receptors alone,
differentially regulate signaling by distinct patterns of β-arrestin recruitment. Using
BRET-based biosensors, we assessed the recruitment kinetics of β-arrestin1/2 to the
AT1R/FP dimer, or the parent receptors alone, when stimulated by either Ang II or PGF2α.
Using cell lines with CRISPR/Cas9-mediated gene deletion, we also examined the role
of G proteins in such recruitment. We observed that Ang II induced a rapid, robust, and
sustained recruitment of β-arrestin1/2 to AT1R and, to a lesser extent, the heterodimer, as
expected, since AT1R is a strong recruiter of both β-arrestin subtypes. However, PGF2α
did not induce such recruitment to FP alone, although it did when the AT1R is present
as a heterodimer. β-arrestins were likely recruited to the AT1R partner of the dimer. Gαq,
Gα11, Gα12, and Gα13 were all involved to some extent in PGF2α-induced β-arrestin1/2
recruitment to the dimer as their combined absence abrogated the response, and their
separate re-expression was sufficient to partially restore it. Taken together, our data
sheds light on a newmechanismwhereby PGF2α specifically recruits and signals through
β-arrestin but only in the context of the AT1R/FP dimer, suggesting that this may be a
new allosteric signaling entity.
Keywords: G protein-coupled receptor (GPCR), dimerization, allosteric regulation, arrestin, angiotensin,
prostaglandin
INTRODUCTION
G protein-coupled receptors (GPCRs) have historically been studied and understood as functional
monomers. Althoughwell-established for class-CGPCRs (1, 2), an increasing body of evidence now
supports that class-A GPCRs also form dimers (3, 4) and even higher-order oligomers; however, the
exact physiological significance, and pharmacological importance of such complexes still remain
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elusive. Given that GPCRs are one of the most successfully
exploited drug targets, the continuing emergence of dimers
represent a promising opportunity not only to better understand
GPCR biology and their roles in disease etiology, but also
to reveal their full therapeutic potential as unique functional
entities (5).
One untapped feature of GPCR dimers might be a potential
ability to assemble according to cellular needs and to combine
two separate, independent orthosteric binding sites—especially
true for heterodimers—where one receptor protomer can
potentially allosterically modulate the function of the other,
and vice-versa. Further, GPCR dimers can also allow different
intracellular signaling partners to selectively interact with only
one of the two protomers or both, expanding the possibilities
for the cell to adapt to different conditions. For example, a
D2 dopamine receptor homodimer was found to be organized
asymmetrically with respect to its G protein partners such that
occupation of the first protomer facilitated downstream cellular
signaling through the second protomer, while occupation of
the latter (or even its constitutive activity) modulated signaling
allosterically without inducing a signal on its own (6). In the
context of such a functional dimeric assembly, benefits usually
attributed to allosteric modulators can be derived from an
otherwise orthosteric site, offering novel avenues to fine-tune
signaling efficacy, improve receptor subtype selectivity and tissue
specificity as well as off target effects (7).
For most class-A GPCR dimers, the minimal signaling
unit is thought to be composed of two receptors and one
heterotrimeric G protein to form a pentameric structure (3, 4, 6).
Interestingly, monomeric GPCRs have recently been found to
also form what is called a super-complex, or “megaplex,” by
simultaneously binding through its core region with G protein
and through its phosphorylated C-terminal tail with β-arrestin
(8); therefore, opening the possibility for GPCR dimers to
form higher-order oligomeric complexes with both G protein
and β-arrestin. Indeed, β-arrestin has been demonstrated to
adopt two distinct conformations when bound to an engineered
β2-adrenergic receptor (β2AR) (9). β-arrestin adopts a more
engaged “core” conformation in which it contacts extensively
with the transmembrane domains, the intracellular loops along
with the phosphorylated C-terminal tail of the receptor, and
a more relaxed conformation (“core” conformation) in which
it contacts with the receptor C-terminal tail only, allowing β-
arrestin to more freely hang from the receptor and exposing
the entire intracellular surface (9). Some crystal structures of
GPCRs also appear to support the formation of “megaplex.”
An arrangement similar to the “core” conformation have been
reported in a rhodopsin/visual arrestin crystal structure (10),
while the β2AR/Gs protein crystal structure seems compatible
with the “tail” conformation and the simultaneous presence of
G protein and β-arrestin (11).
Abbreviations: GPCR, G protein-coupled receptor; Ang II, angiotensin; AT1R,
angiotensin II type I receptor; PGF2α, prostaglandin 2α; FP, prostaglandin 2α
receptor; BRET, bioluminescence resonance energy transfer; FlAsH, fluorescein
arsenical hairpin binder; RlucII, Renilla luciferase II.
A hurdle in investigating class-A GPCR dimerization has been
the limited capacity to identify the respective function of the
protomers within a dimer, that is which protomer binds the
ligand and which protomer signals. This minimal functional unit
is used to investigate the interplay between β-arrestin 1/2 and
multiple G proteins at the larger intracellular interface of a GPCR
dimer using a panel of BRET-based biosensors. We previously
showed that AT1R and FP could be co-purified together using
immunoprecipitation in HEK 293 cells and in vascular smooth
muscle cells combined with photoaffinity labeling (12). We
noted that FP antagonists resulted in inhibition of Ang II-
mediated contraction, an effect that cannot be mediated by
second messenger-activated crosstalk via protein kinases, since
these ligands did not activate such signaling events. Similar
results were obtained when we pre-treated cells with an AT1R
antagonist when measuring FP-mediated contraction (12).
We also engineered FlAsH tags and Renilla luciferase into
both AT1R and FP and co-expressed them with their untagged
counterparts (13). We again noted asymmetric transmission of
conformational information between protomers. AT1R-induced
conformational rearrangements in FP were dependent on
both the presence of activatable Gαq as well as the possible
involvement of phospholipase Cβ, a proximal Gαq-effector.
Association of GPCRs, G proteins and effectors likely represent
core units of signaling complex organization, which is reflected
by mutual allosteric effects. We also showed that AT1R-driven
conformational changes in FP were independent of the activation
of PKC, a shared downstream receptor signaling pathway.
Allosteric interactions occur in the plasma membrane, mediated
through a shared G protein in a heterodimer. The AT1R/FP
heterodimer remained intact even in the absence of Gαq, thus
they are not required for assembly of receptor heterodimers
rather allosterically connecting the two receptors as part of
signaling complexes. With respect to allosteric interactions in the
AT1R/FP dimer, AT1R was able to modulate FP conformation
but the converse was not true (at least with the biosensors
we were using) (14). Further, the AT1R to FP conformational
crosstalk in the heterodimer was biased toward Gαq/11 as a
preferred heterodimer partner, as no conformational effects were
observed when Gα12/13 or Gαi function or levels were altered.
Such a perceived coupling preference in the heterodimer might
again be because our initial panels of conformational biosensors
may have only been sensitive to the presence of particular G
proteins. Here, we extend this finding to β-arrestin to show how
this scaffolding/adaptor protein can be symmetrically (e.g., cis-
activation) and asymmetrically (e.g., trans-activation) regulated
in response to Ang II and PGF2α, respectively.
MATERIALS AND METHODS
Materials
All cell culture media, reagents, and antibiotics were fromWisent
Inc. (St-Bruno, Québec, Canada). All DNA primers for molecular
cloning were custom-made by Integrated DNA Technologies
Inc. (Coralville, IA, USA). All enzymes and other materials
used for molecular cloning were from New England Biolabs
Ltd. (Ipswich, MA, USA), except for the Pvu II and Taq I
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restriction enzymes that were both from Takara Bio Inc. (Noji
Higashi, Kusatsu Shiga, Japan). Cell transfection reagent was
from Invitrogen, Thermo Fisher Scientific Inc. (Waltham, MA,
USA). All chemicals, including Ang II and the AT1R antagonists
were from Sigma-Aldrich Inc. (St. Louis, MO, USA) unless
otherwise specified. PGF2α and cloprostenol were from Cayman
Chemical Company (AnnArbor,MI, USA). Coelenterazine hwas
from NanoLight Technologies (Pinetop, AZ, USA).
CRISPR-Gene Deletion Lines
As recently reported (14), the HEK 293 1Gαq/11/12/13 cell line
wherein all the genes encoding for Gq, G11, G12, and G13
proteins have been knocked out was generated by simultaneously
targeting the GNA12 and the GNA13 genes of the previously
established HEK 293 1Gαq/11 cells (15), using CRISPR/Cas9 as
described previously (16).
Molecular Cloning and Mutagenesis
The following plasmids pcDNA3/SP-FLAG-hAT1R-WT (12),
pcDNA3.1/SP-FLAG-hAT1R-RlucII (17), pcDNA3/SP-HA-hFP-
RlucII (18), β-arrestin 1-RlucII (19, 20), β-arrestin 2-RlucII
(19, 20) were used. A K44 dynamin mutant in pcDNA3 was
a generous gift from Dr. Denis Dupré (Dalhousie University).
The different pcDNA3.1 plasmids encoding Gαq, Gα11,
Gα12, Gα13 were from UMR cDNA resource center (www.
cdna.org; University of Missouri-Rolla, Rolla, MO, USA).
The pcDNA3.1/SP-FLAG-hAT1R-KPVAT-Venus plasmid
was created from pcDNA3/SP-FLAG-hAT1R-WT that was
amplified by PCR using the forward primer 5′-CCTAGCTAG
CTCGAGGCCACCATGAACACGATCATC-3′ and reverse
primer 5′-TACCGGTGGCGACCGGTTTCTCAACCTCAA
AACATGGTGC-3′ (without a stop codon). The purified PCR
fragment obtained was then subcloned in-frame into the NheI
and AgeI restriction sites located in 5′ and 3′, respectively,
of pcDNA3.1/Venus, which was a kind gift from Dr. Michel
Bouvier (Université de Montreál, Montréal, Canada). In a same
way, the pcDNA3.1/SP-FLAG-hAT1R[1325]-KPVAT-Venus
plasmid was generated using the forward primer 5′-CCTAGCT
AGCTCGAGGCCACCATGAACACGATCATC-3′ and reverse
primer 5′-AAAGGGTGGCGACCGGTTTGGCTTTTGGGG
GAATATATTTTAGAAGCTG-3′ (without a stop codon) to
amplified pcDNA3/SP-FLAG-hAT1R-WT, and the resulting
PCR fragment was then subcloned into the same restriction sites
of pcDNA3.1/Venus. The HA-hOTR-Venus plasmid was made
by the PCR amplification of a previously described hOTR-YFP
construct (21) using the forward primer 5′-TTATGCCTGC
GGATCCGAGGGCGCGCTCGCAGCCAACT-3′ and reverse
primer 5′-CGCCACCTCCGGATCCCGCCGTGGATGGCT
GGGA-3′. The purified PCR fragment obtained was then
digested at the BamHI restriction site, and subcloned in-frame
by recombination into pIRESpuro3/HA-Venus using the In-
Fusion cloning system from Clontech Laboratories (Mountain
View, CA, USA). The pcDNA3.1/SP-HA-hFP-WT plasmid was
prepared by two rounds of PCR. First, a previously described
pIRESpuro3/HA-hFP-WT construct (18) was amplified using
the forward primer 5′-ATGAACACGATCATCGCCCTGA
GCTACATCTTCTGCC-3′ and reverse primer 5′-ATCC
GAATTCCTAGGTGCTTGCTGATTTCTCTGC-3′. The
purified PCR fragment was submitted to a second round of
PCR amplification using the forward primer 5′-CCTAGCTAGC
TCGAGGCCACCATGAACACGATCATC-3′ and the same
reverse primer. The resulting PCR fragment was then purified
and digested at the XhoI and EcoRI restriction sites located at
the 5′ and 3′, respectively, and subcloned into pcDNA3.1 from
Invitrogen (Waltham, MA, USA). The pcDNA3.1/SP-HA-hFP-
KPVAT-Venus plasmid was produced using the forward primer
5′-CCTAGCTAGCTCGAGGCCACCATGAACACGATCATC-
3′ and reverse primer 5′-GGTGGCGACCGGTTTGGTGCTTG
CTGATTTTGC-3′ to amplify pcDNA3.1/SP-HA-hFP-WT by
PCR. The purified PCR fragment was then digested at the NheI
and AgeI restriction sites located in 5′ and 3′, respectively, and
subcloned into pcDNA3.1/Venus. All constructs were verified
by bidirectional DNA sequencing. The constructs for enhanced
bystander BRET to examine AT1R and FP trafficking, Lyn-rGFP,
and rGFP-FYVE were used as previously described (17).
Cell Culture and Transient Transfection
The HEK 293 parental and1Gαq/11/12/13 cell lines were cultured
in 75 cm2 plastic flasks containing Dulbecco’s Modified Eagle’s
Medium (DMEM) high glucose supplemented with 5% (v/v)
fetal bovine serum (FBS) and 1% (w/v) penicillin–streptomycin
(P-S) antibiotics. Cells were cultured in a controlled, humidified
environment maintained at 37◦C and 5% CO2 atmosphere
until a confluency of 80–100% was reached. For transfection,
cells were trypsinized, and 125,000 cells/well in 1mL of the
same fresh media were seeded into 12-well plates. Cells were
incubated overnight in at 37◦C. After 24 h, media from the
plate was replaced by 1 mL/well of DMEM supplemented
with 5% (v/v) FBS. Cells were transfected with the appropriate
plasmids encoding for AT1R (0.3 µg/well), FP (0.1 µg/well),
and the sensors (β-arrestin 1/2-RlucII (0.0025–0.025 µg/well),
along with pcDNA3.1(-) for a total of 1.0 µg per well
using Lipofectamine R© 2000 [2.5(Lipo2000):1(DNA) ratio] and
following the manufacturer’s instructions. Twenty-four hours
post-transfection, the cells were trypsinized, and 40,000–50,000
cells/well were transferred into white 96-well plates (Costar R©
#3917, Corning, NY, USA) previously coated with poly-L-
ornithine hydrobromide (Sigma-Aldrich Inc., St. Louis, MO,
USA). Cells were left in a cell culture incubator for another
24 h before performing the experiments. Mycoplasma testing was
carried out periodically on all cell lines using the MycoAlertTM
kit from Lonza (Rockland, MD, USA).
Bioluminescence Resonance Energy
Transfer (BRET) Assay
BRET experiments were performed as described elsewhere (13,
14, 18, 22, 23). For intermolecular BRET experiments, energy-
donor proteins were fused to Renilla luciferase (Rluc) II and
energy-acceptor proteins were fused to the yellow florescent
protein (YFP). In all experiments, coelenterazine h was used
as the Rluc/RlucII substrate to generate light with a maximal
emission peak at 480 nm, allowing YFP excitation. In a typical
experiment, transfected cells from a white 96-well plate were
carefully washed once with 150 µL of Kreb’s buffer [146mM
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NaCl, 4.2mMKCl, 0.5mMMgCl2, 1mMCaCl2, 5.9mM glucose,
and 10mM HEPES pH 7.4, 0.1% (v/v) glucose], and then the
cells were incubated in the absence (i.e., with only Kreb’s buffer
alone) or presence (i.e., with AT1R antagonists or endocytosis
inhibitors) of pretreatments in 95µL/well of the same fresh Kreb’s
buffer. The plate was protected from light, and the cells were
incubated for 1 h at 37◦C for BRET experiments which were
conducted at 37◦C. A TriStar² LB 942 multimode microplate
reader from Berthold Technologies Inc. (Bad Wildbad, 75323,
Germany) equipped with the predetermined BRET1 filter pair
F485/F530, and a VICTOR X-light multilabel plate reader from
Perkin Elmer Inc. (Waltham, MA, USA) equipped with the
predetermined BRET1 filter pair F460/F535 nm (200 msec./filter,
alternatively) were used to measure BRET ratios. For enhanced
bystander BRET we used 410 nm (donor) and 515/40 nm
(acceptor) filters. Under these conditions, both plate readers were
able to complete one cycle of BRET ratio measurement in 2min
for a 96-well plate. Experiments with 96-well plates were also
carried out at once following four consecutive steps in a timely
fashion so that a same time interval apply between each well
throughout the process: (1) adding the coelenterazine h substrate
for light generation (using a repeater pipette); (2) measuring the
BRET ratios of basal, unstimulated cells; (3) stimulating the cells
with either vehicle or ligand (using a multichannel pipette); (4)
measuring the BRET ratios of stimulated, ligand-induced cells.
Following a 1 h incubation in Krebs buffer, 25µL/well of a 30µM
coelenterazine h solution (for a final concentration of 5µM) was
sequentially added to the cells so it takes 2min to fill up the
entire 96-well plate. The basal, unstimulated BRET ratios were
then immediately measured over a period of 10min (5 measuring
cycles). Upon completion, the 96-well plate was rapidly removed
from the plate reader, and 30 µL/well of either vehicle or 5µM
ligand (e.g., Ang II or PGF2α, for a final concentration of 1µM
in 150 µL) was sequentially added to the cells so, again, it takes
2min to fill up the entire 96-well plate. The ligand-induced BRET
ratios were then immediately measured over a period of 90min
(45 measuring cycles).
Data Analysis
BRET ratios were calculated as BRET = λ530 or 535/λ485 or 460,
and ligand-induced BRET changes as 1BRET = BRETLigand −
BRETVehicle. Conditions associated with ligand and vehicle were
performed in triplicate (i.e., 3-wells each) for each biological
replicate, and averaged data were used in all calculations. As
shown in the figures, BRET data were reported as kinetic traces
or bar graphs integrating the area under the curve. Statistical
analysis and curve fitting were all carried out using the GraphPad
PRISM software v6.0 (La Jolla, CA, USA). For Figure 1, half-time
values were calculated using a one-phase association equation
and a least squares method to fit the data on a curve by
non-linear regression. For Figure 2, 1BRET data were fit on a
curve by non-linear regression using a one-phase exponential
dissociation decay and a least squares method. Statistical analysis
on normalized 1BRET data was performed using a Mann-
Whitney U-test (p < 0.05), followed by a post-hoc Dunn’s test
to correct for multiple comparisons (all conditions vs. 0 µg).
For Figure 4 statistical analysis on 1BRET data was performed




PGF2α 7.2 × 10−9 ± 6.9 × 10−10
AL-8810 3.0 × 10−6 ± 1.6 × 10−6
Cloprostenol 1.8 × 10−10 ± 5.2 × 10−11
Fluprostenol 8.9 × 10−10 ± 7.2 × 10−11
Latanoprost 6.1 × 10−9 ± 1.2 × 10−9
Tafluprost 4.8 × 10−10 ± 1.1 × 10−10
HEK 293 parental cells transiently expressing β-arrestin 2-RlucII, AT1R-Venus, and FP-
WT dimer were assayed as described in section Materials and Methods. Data represent
mean ± s.e.m. of independent experiments performed in triplicate (n = 3).
using an unpaired Student’s t-test (p < 0.01), followed by a
post-hoc Bonferroni test to correct for multiple comparisons (all
conditions vs. PGF2α or cloprostenol). EC50 values from Table 1
were calculated with the following three parameter equation:
Response = Bottom + [(Top - Bottom) / (1 + 10(logEC50
− log[A])], where Top and Bottom represented maximal and
minimal asymptotes of the curve, [A] is the agonist concentration
expressed in (M) and EC50 is the agonist concentration (M) that
generated a response half way between the top and bottom.
RESULTS
Symmetric and Asymmetric β-Arrestin
Recruitment Mediated by Ang II and
PGF2α, Respectively
We used BRET-based biosensors to examine real-time
recruitment of β-arrestin 1/2-RlucII to AT1R-Venus alone,
FP-Venus alone, and the AT1R/FP dimer wherein Venus was
fused to either AT1R or FP. Ang II stimulation induced a
rapid, robust, and sustained β-arrestin 1/2-Rluc recruitment
to AT1R-Venus alone (Figure 1A) typical of a class-B GPCR
interaction with β-arrestin (24). While showing an identical
kinetic profile, co-expression of FP-WT to form the putative
AT1R-Venus/FP-WT dimer dampened the extent of β-arrestin
recruitment (Figure 1A). However, we cannot say with certainty
that this effect is not due to reduced AT1R expression in the
presence of co-expressed FP or simply a different physical
spacing of BRET donor and acceptor caused by formation
of the heterodimer. β-arrestin recruitment could blocked by
the AT1R antagonist losartan and was not detected using a
mutated AT1R[1325]-Venus with a markedly reduced ability
to recruit β-arrestin (Figure 1B). On the other hand, in the
AT1R-WT/FP-Venus dimer configuration, however, Ang II
failed to recruit β-arrestin 1/2-Rluc (Figure 1A). Altogether,
these findings suggest that Ang II occupancy of the AT1R/FP
dimer induced a recruitment of β-arrestin 1/2 that is symmetric,
or cis, to the AT1R protomer, and that FP may act to reduce
this response. By way of comparison, PGF2α stimulation did
not induce recruitment of β-arrestin 1/2-Rluc to FP alone, as
previously shown (25, 26), or to the AT1R-WT/FP-Venus dimer
Frontiers in Endocrinology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 162
Fillion et al. β-Arrestin Recruitment to FP/AT1R Heterodimer
FIGURE 1 | Symmetric and asymmetric recruitment of β-arrestin 1/2 to the AT1R/FP dimer by Ang II and PGF2α, respectively. (A) Ang II (1µM) induced a rapid and
sustained symmetric recruitment of β-arrestin 1-RlucII (dashed lines; t1/2 < 2min.) and β-arrestin 2-RlucII (full lines; t1/2 < 2min) to AT1R-Venus alone (purple lines)
and to a lesser extent, the AT1R-Venus/FP-WT dimer (blue lines), but not to the AT1R-WT/FP-Venus dimer (black lines). (B) No and very small responses were
detected with Ang II by blocking AT1R-Venus with losartan (100µM) (dashed and full blue lines), and when an AT1R[1325]-Venus mutant deficient for both β-arrestin
1/2-RlucII recruitments (dashed and full blue-green lines) were used in the context of the dimer, respectively. Responses were all specific to AT1R since no responses
were detected for FP-Venus alone (dashed and full red lines) and β-arrestin 1/2-RlucII alone (dashed and full black lines). (C) PGF2α (1µM) induced a slower, yet
sustained asymmetric recruitment of βarr1-RlucII (dashed blue lines; t1/2 = 20min) and β-arrestin 2-RlucII (full blue lines; t1/2 = 17min) to the AT1R-Venus/FP-WT
dimer only, but not to FP-Venus alone (dashed and full red lines) and the AT1R-WT/FP-Venus dimer (dashed and full black lines). (D) No responses were detected with
PGF2α when OTR-Venus (dashed and full blue lines) and an AT1R[1325]-Venus mutant deficient for both β-arrestin 1/2-RlucII recruitment (dashed and full blue-green
lines) were used in the context of the dimer. Responses were all specific to FP since no responses were detected for AT1R-Venus (dashed and full red lines) and
β-arrestin 1/2-RlucII alone (dashed and full black lines). Data represent mean ± s.e.m. of independent experiments [biological replicates, each performed in triplicate
(n = 3–15)].
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FIGURE 2 | Specificity of the PGF2α-induced β-arrestin 2 recruitment to the
AT1R/FP dimer. The recruitment of β-arrestin 2-RlucII to the AT1R-Venus (0.3
µg)/FP-WT (0.1 µg) dimer (fixed amount) induced by PGF2α (1µM) was
titrated by co-transfecting increasing amounts of AT1R-WT (0.0–0.7 µg).
Increased expression of AT1R-WT competed with AT1R-Venus for
dimerization with FP-WT, reducing the capacity of the AT1R-Venus/FP-WT
dimer to recruit β-arrestin 2-RlucII. Data were normalized for AT1R-Venus
expression and represent mean ± s.e.m. of independent experiments
[biological replicates each performed in triplicate (n = 3–5)]. *p < 0.05,
compared to AT1R-WT (0.0 µg).
(Figure 1C). Interestingly, however, it induced a comparatively
slower, less robust, yet prolonged β-arrestin 1/2-Rluc recruitment
to the AT1R-Venus/FP-WT than Ang II did, suggesting this
time that the PGF2α occupancy of FP recruits β-arrestin 1/2
to its AT1R partner protomer in an asymmetrical, or trans,
fashion (Figure 1C). Recruitment of β-arrestin was not seen
when FP-WT was co-expressed in the context of a dimer
with β-arrestin 1/2 recruitment-deficient AT1R[1325]-Venus
mutant or another peptidergic class-A GPCR, the oxytocin
(OT) receptor (OTR, Figure 1D). We previously showed that
OTR does not dimerize with FP (13) so results presented here
are consistent with this earlier study. In all cases, β-arrestin 2
was shown to be a better responder than β-arrestin 1 for both
Ang II and PGF2α stimulation (Figures 1A,C). All responses
were also specific since no recruitment was detected when
AT1R alone or FP alone were stimulated with their non-cognate
ligands (Figures 1B,D), or when β-arrestin 1/2-RlucII were
transfected alone. Furthermore, the PGF2α-induced recruitment
of β-arrestin 2-RlucII to the AT1R-Venus/FP-WT dimer was
titrated by coexpression of increasing amounts of AT1R-WT to
disrupt the reporting dimer by competition, demonstrating the
specificity of AT1R-Venus/FP-WT dimer formation critical for
asymmetric recruitment of β-arrestin 2 (Figure 2).
In order to provide an independent measure of how the
dimer resulted in a new ability for FP to induce trafficking of
the AT1R/FP dimer, we used enhanced bystander BRET (17) to
follow association of AT1R-RlucII or FP-RlucII with a membrane
BRET acceptor (Lyn-rGFP) or early endosome acceptor (rGFP-
FYVE). In the case where AT1R-RlucII was co-expressed with
WT FP and either of the BRET acceptors, stimulation with
either Ang II (Figure 3A) or PGF2α (Figure 3B) led to a time-
dependent loss of the membrane signal and an increase in the
endosomal population. When FP-RlucII was co-expressed with
WT-AT1R and the two BRET acceptors, again PGF2α induced a
loss of membrane-localized receptor and a transient increase in
an early endosomal population (Figure 3C). This suggests that
the two ligands might drive receptors into different trafficking
itineraries, discussed below. We also attempted to measure what
would happen when we stimulated this combination of receptors
(FP-RlucII and WT-AT1R) with Ang II. There was little change
in bystander BRET for either location-specific biosensor likely
because in our hands the AT1R expresses so much better than
the FP and thus most of the AT1R in this configuration was not
coupled to FP (data not shown).
Next, we assessed to what extent the AT1R-Venus/FP-WT
dimer could asymmetrically recruit the β-arrestin 2-Rluc by
examining a panel of five chemically distinct FP ligands, some
of which have clinical indications (27). Except for AL-8810, all
the ligands we tested, cloprostenol, fluprostenol, latanoprost,
and tafluprost, were found to recruit β-arrestin 2-Rluc in an
asymmetric fashion with EC50 values in the low nanomolar to
the picomolar range (Table 1). While all the other tested ligands
exhibit full agonist properties, AL-8810 is the only one shown to
display partial agonist properties (28), and had an EC50 value
for β-arrestin 2-RlucII recruitment in the micromolar range
(Table 1). Further, as AL-8810 promotes activation of ERK1/2
by transactivation of the epidermal growth factor receptor (25),
this may be possible explanation for this discrepancy. It is clear,
however, that a number of FP ligands can recruit β-arrestin to
the dimer.
Having previously shown allosteric crosstalk between FP
and AT1R in that antagonists for either receptor modulated
signaling via the partner receptor, we next tested how different
AT1R antagonists modulated PGF2α-mediated recruitment of
β-arrestin to the dimer. PGF2α responses were regulated by
both temilsartan and azilsartan (Figure 4A), while cloprostenol
responses were regulated by temilsartan only (Figure 4B). On
the other hand, other AT1R antagonists we tested, irbesartan,
candersartan, and losartan, did not allosterically modulate the
responses induced by either PGF2α or cloprostenol.
G Proteins Alter the Extent of β-Arrestin
Recruitment
Using a HEK 293 line with deletion of Gq/11 and G12/13 (13),
we next assessed how different G proteins might be involved in
recruitment of β-arrestin to the FP/AT1R dimer. Ang II-induced
recruitment of β-arrestin 1/2-RlucII to the AT1R-Venus/FP-WT
dimer was measured in the parental and the 1Gαq/11/12/13
cell line. The absence of G proteins reduced Ang II-induced
response by approximately 50% for β-arrestin 1 and β-arrestin 2
(Figures 5A,B). Individual G proteins were then restored to the
1Gαq/11/12/13 cell line to assess which might be able to rescue
this loss of β-arrestin recruitment. Replacement of Gα11, Gα12, or
Gα13 partially rescued β-arrestin 1 recruitment but surprisingly,
not Gαq (Figure 5A). A similar finding was noted for β-arrestin
2 (Figure 5B). Although the data were considerably noisier for
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FIGURE 3 | Enhanced bystander BRET shows FP can stimulate AT1R
internalization. HEK293 cells were transfected with the indicated enhanced
BRET pairs. To monitor AT1R- or FP-mediated trafficking of AT1R-RlucII from
the membrane (loss of Lyn-rGFP bystander BRET) or endosomal trafficking (as
measured by increase in rGFP-FYVE bystander BRET), AT1R-RlucII were
co-transfected with wildtype FP and the indicated bystander BRET partner.
Cells were stimulated with (A) 1µM Ang II or (B) 1µM PGF2α and monitored
over time. (C) FP-RlucII were co-transfected with wildtype AT1R and the
(Continued)
FIGURE 3 | indicated bystander BRET partner and stimulated with 1µM
PGF2α and monitored over time. BRET signals were measured as described in
Materials and Methods. Data represent mean ± s.e.m. of independent
experiments performed in triplicate (n = 3).
the responses measured after treatment with PGF2α, similar
patterns were detected for β-arrestin 1 recruitment (Figure 5C,
also see inset). Interestingly, in this case, re-expression of any
of the four Gα subunits was able to partially rescue β-arrestin 2
recruitment mediated by PGF2α (Figure 5D). Although we did
not control for expression of the different G protein subunits,
these data suggest a complicated interplay between G protein and
β-arrestin coupling, inconsistent with a simple interpretation of
these events.
Spatiotemporal Aspects of Differential
β-Arrestin 1 Recruitment to the FP/AT1R
Heterodimer
We previously showed that stimulation of the receptor pair with
either ligand resulted in receptor internalization of the dimer
when reconstituted using a split Venus protein complementation
(12). The data in that paper, using confocal imaging, hinted that
distinct endocytic routes might be taken in response to PGF2α
compared to Ang II. Given the role of β-arrestin recruitment in
the post-stimulation trafficking of receptors, we examined how
different inhibitors of endocytosis affected interactions between
the FP/AT1R heterodimer and β-arrestin1/2. As before, we first
examined the effects of Ang II on β-arrestin1/2 recruitment.
In both cases, neither concanavalin A or a dominant negative
dynamin K44 mutant had significant effects compared to control
(Figures 6A,B). However, the extent of the recruitment of
β-arrestin was decreased significantly by phenylarsine oxide
and potentiated by sucrose. The responses to PGF2α were
qualitatively different. In this case, again there was no effect of
dynamin K44, but both sucrose and phenylarsine oxide reduced
β-arrestin1/2 recruitment while concanavalin A potentiated the
interaction (Figures 6C,D). These results again suggest that the
trafficking itineraries of the heterodimer are distinct following
stimulation with either Ang II or PGF2α. Taken together our data
suggest that the dimer adopts different fates when stimulated by
distinct ligands.
DISCUSSION
Here, we show that two ligands binding to different sites in
a GPCR heterodimer elicit asymmetric responses with respect
to β-arrestin1/2 recruitment. Although FP does not normally
recruit β-arrestin1/2 (12, 26), as there are GPCRs that don’t
recruit β-arrestin (29), stimulation of FP can recruit β-arrestin
to an AT1R partner in the context of a heterodimer. Further,
we show that different ligands acting on receptor dimers may
lead to qualitatively distinct β-arrestin1/2 recruitment events
with potentially distinct trafficking itineraries. Such observations
might help to explain the functional asymmetries we’ve noted in
our previous study (12). Our data add a new wrinkle to signaling
via GPCR heterodimers, when we consider how structural and
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FIGURE 4 | Biased allosteric regulation of the PGF2α- and cloprostenol-induced β-arrestin2 recruitment to the AT1R/FP dimer by AT1R antagonists. (A) Pretreatment
(1µM for 30min) with telmisartan or azilsartan allosterically inhibited recruitment of β-arrestin 2-RlucII to the AT1R-Venus/FP-WT dimer in response to PGF2α (1µM).
Under the same experimental conditions, irbesartan, candersartan and losartan produced no allosteric effects. (B) Pretreatment (1µM for 30min) with telmisartan
allosterically inhibited the recruitment of β-arrestin 2-RlucII to the AT1R-Venus/FP-WT dimer in response to cloprostenol (1µM). Under the same experimental
conditions, azilsartan, irbesartan, candersartan and losartan produced no allosteric effects. Data represent mean ± s.e.m. of independent experiments [biological
replicates performed in triplicate (n = 3–6)]. *p < 0.05. N.S., non-significant.
functional asymmetries might play out in terms of bi-directional
allosteric receptor regulation.
Previously, we showed that the AT1R and FP formed
heterodimers in both HEK 293 and vascular smooth muscle cells
(VSMC) where they are endogenously co-expressed.We analyzed
several phenotypic responses, including MAPK activation and
DNA and protein synthesis in both HEK 293 cells and in VSMC.
We showed AT1R when treated with an antagonist strongly
potentiated ERK1/2 activation by FP, which was not reciprocated
by treatment of FP with its own antagonists when measuring
Ang II-mediated ERK1/2 activation (12). We also used [3H]-
thymidine incorporation as a measure of DNA synthesis, and
[3H]-leucine incorporation as a measure of protein synthesis
and observed that pre-treatment of VSMC with an AT1R
antagonist on [3H]-thymidine incorporation following PGF2α
stimulation could be inhibited by FP blockade, but not by
AT1R blockade. However, the FP antagonist was as efficient as
the AT1R antagonist in inhibiting both Ang II-induced [3H]-
thymidine or [3H]-leucine incorporation (12). These results
highlighted an important asymmetry in the regulation of
cellular responses via the receptor heterodimer. This was also
reflected in our conformational profiling of both receptors using
the FlAsH-BRET approach where conformational information
could be transferred from the AT1R through to FP via a
shared G protein but the converse could not be detected.
Distinct patterns of β-arrestin1/2 recruitment might be at the
root of some of the functional asymmetries. Interestingly, a
number of GPCR dimers have been demonstrated to recruit
β-arrestin1/2 [reviewed in (30)], although whether asymmetries
in β-arrestin1/2 recruitment, such as we have measured here have
yet to be assessed systematically with respect to other homo-
or heterodimers.
Deletion of several Gα subunits significantly abrogated both
Ang II- and PGF2α-mediated β-arrestin1/2 recruitment which
was in all cases restored by re-expression of Gα11, Gα12, or Gα13
but not always Gαq. This is odd, as Gαq is a well-known partner
for both receptors. We identified Gαq/11 as the conduit by which
allosteric information was transferred from AT1R to FP which
did not occur in the opposite direction from FP to AT1R (13).
Perhaps this is a reflection of a similar asymmetry. It is also one
of the rare instances where a distinction could be made between
Gα11 and Gαq. Recent studies have suggested we need to be
circumspect about cells gene-deleted for different G proteins that
may get “rewired” as a consequence (31). More systematic studies
with better controlled levels of G protein expression would be
necessary to confirm our findings, but it is clear that changes
to β-arrestin1/2 recruitment in the gene-deleted cells used in
this study could be partially rescued by restoring individual
Gα subunits.
We had previously shown that the trafficking of the
putative heterodimer was likely different depending on
whether stimulation was via Ang II or PGF2α (12). We
noted here that they had distinct sensitivities to different
inhibitors of endocytic processes. In response to Ang II, the
β-arrestin interaction was inhibited by phenylarsine oxide,
a compound whose exact mechanism of action is unknown
(32), and potentiated by hypertonic sucrose suggesting
that in the latter case, more β-arrestin can be recruited
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FIGURE 5 | Role of G proteins in Ang II- and PGF2α-induced β-arrestin 1/2 recruitment to the AT1R/FP dimer. (A,B) Compared to the HEK 293 parental cell line
(black lines), Ang II (1µM) induced a decaying and much lower, yet sustained recruitment of β-arrestin 1/2-RlucII to the AT1R-Venus/FP-WT dimer when evaluated in
the HEK 293 1Gαq/11/12/13 cell line (red lines). (C,D) PGF2α (1µM) induced the recruitments of β-arrestin 1/2-RlucII to the AT1R-Venus/FP-WT dimer in the HEK
293 parental cell line (black lines) only, and virtually no responses were detected with the HEK 293 1Gαq/11/12/13 cell line (red lines) (C), inset: The response in
parental and 1Gαq/11/12/13 cell lines are shown alone for clarity. Data represent mean ± s.e.m. of [biological replicates performed in triplicate (n = 3–15)].
in this case, that is the receptors still remain accessible to
β-arrestin because they are not being internalized. Cells
treated with phenylarsine oxide might be compromised with
respect to G protein dissociation required for β-arrestin
recruitment. In response to PGF2α, however, the pattern
of inhibition was distinct, suggesting again that receptors
were locked into a distinct trafficking itinerary, yielding two
distinct fates for the same receptor complex activated by
different ligands.
Similar asymmetric structural arrangements were also
observed in other GPCR oligomers including the luteinizing
hormone receptor (33), rhodopsin (34), mGluR2/3 heterodimers
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FIGURE 6 | Effects of endocytosis inhibitors on Ang II- and PGF2α-induced β-arrestin 1/2 recruitment to the AT1R/FP dimer. (A,B) Sucrose (blue lines, 450mM) and
phenylarsine oxide (blue-green lines, 2.5µM) pretreatment (30min) potentiated and diminished the recruitment of β-arrestin1/2-RlucII to the AT1R-Venus/FP-WT dimer
in response to Ang II (1µM), respectively. To a much lesser extent, concanavalin A (purple lines, 0.4 g/L) pretreatment (30min) and the dominant negative mutant
K44A dynamic (salmon lines; 0.5 µg) also potentiated and diminished the responses, respectively. (C,D) Concanavalin A (purple lines, 0.4 g/L) and phenylarsine oxide
(blue-green lines, 2.5µM) pretreatment (30min) potentiated and diminished the recruitments of β-arrestin 1/2-RlucII to the AT1R-Venus/FP-WT dimer in response to
PGF2α (1µM), respectively. To a lower extent, sucrose (blue lines, 450mM) and the dominant negative mutant K44A of dynamin (salmon lines; 0.5 µg) both
diminished the responses. Data represent mean ± s.e.m. of independent experiments performed in triplicate (n = 3–4).
(1), and leukotriene B4 receptor dimers (35). These studies
indicate that individual protomers in GPCR dimers and
oligomers could interact with shared G proteins via distinct
interfaces [see also (6)], providing a mechanism by which such
structural asymmetries could lead to asymmetries in receptor
conformation and functional outcomes. Such asymmetric
conformational crosstalk may provide novel ways to imagine
targeting heterodimers, which has been ignored in current drug
discovery programs.
Other studies showed that AT1R may be an example of
a dimer hub (36) with many different partners such as CB1
cannabinoid receptors (37) apelin receptors, α2CAR, and β2AR
receptor heterodimers (38–42). A more complete exploration
of signaling and conformational profiles in GPCR heterodimers
would get at the full scope of the impact of receptor protomers on
one another.
TheAT1R is an important target for treatment of hypertension
and heart failure and angiotensin receptor blockers remain
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widely prescribed (43). A role for FP in the regulation of blood
pressure has also been suggested (44). FP has been implicated
in parturition with enhanced PGF2α signaling initiating labor
through the stimulation of myometrial contraction (45, 46). The
AT1R is co-expressed in the myometrium and increased levels
have been detected during pregnancy (47–49). Further study of
this putative receptor heterodimer could yield novel drug targets
for a number of diseases.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or the supplementary files.
AUTHOR CONTRIBUTIONS
DF and TH designed the study. DF, DD, and RS performed the
experiments, analyzed the data, and generated the figures. TH,
DF, DD, and AI wrote and edited the paper.
ACKNOWLEDGMENTS
This work was supported by grants from the Canadian Institutes
for Health Research (CIHR) to TH. DF was supported by a
Ferring Fellowship in Reproductive Health. RS was supported by
scholarships from the McGill CIHR Drug Development Training
Program. We also thank Dr. Nicolas Audet (McGill University,
Montréal) for useful discussions regarding statistical analysis.
REFERENCES
1. Levitz J, Habrian C, Bharill S, Fu Z, Vafabakhsh R, Isacoff EY.
Mechanism of assembly and cooperativity of homomeric and
heteromeric metabotropic glutamate receptors. Neuron. (2016) 92:143–59.
doi: 10.1016/j.neuron.2016.08.036
2. WuH,Wang C, Gregory KJ, Han GW, ChoHP, Xia Y, et al. Structure of a class
C GPCRmetabotropic glutamate receptor 1 bound to an allosteric modulator.
Science. (2014) 344:58–64. doi: 10.1126/science.1249489
3. Franco R, Martinez-Pinilla E, Lanciego JL, Navarro G. Basic
pharmacological and structural evidence for class A G-protein-
coupled receptor heteromerization. Front Pharmacol. (2016) 7:76.
doi: 10.3389/fphar.2016.00076
4. Ferre S, Casado V, Devi LA, Filizola M, Jockers R, Lohse MJ, et al. G protein-
coupled receptor oligomerization revisited: functional and pharmacological
perspectives. Pharmacol Rev. (2014) 66:413–34. doi: 10.1124/pr.113.008052
5. Casado V, Cortes A, Mallol J, Perez-Capote K, Ferre S, Lluis C, et al.
GPCR homomers and heteromers: a better choice as targets for drug
development than GPCR monomers? Pharmacol Ther. (2009) 124:248–57.
doi: 10.1016/j.pharmthera.2009.07.005
6. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA. Allosteric
communication between protomers of dopamine class A GPCR
dimers modulates activation. Nat Chem Biol. (2009) 5:688–95.
doi: 10.1038/nchembio.199
7. Smith NJ, Milligan G. Allostery at G protein-coupled receptor homo- and
heteromers: uncharted pharmacological landscapes. Pharmacol Rev. (2010)
62:701–25. doi: 10.1124/pr.110.002667
8. Thomsen AR, Plouffe B, Cahill TJ III, Shukla AK, Tarrasch JT, Dosey AM, et al.
(2016). GPCR-G protein-beta-arrestin super-complex mediates sustained G
protein signaling. Cell. 166:907–19. doi: 10.1016/j.cell.2016.07.004
9. Shukla AK, Westfield GH, Xiao K, Reis RI, Huang LY, Tripathi-Shukla P, et al.
Visualization of arrestin recruitment by a G-protein-coupled receptor.Nature.
(2014) 512:218–22. doi: 10.1038/nature13430
10. Kang Y, Zhou XE, Gao X, He Y, Liu W, Ishchenko A, et al. Crystal structure
of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature. (2015)
523:561–7. doi: 10.1038/nature14656
11. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al.
Crystal structure of the beta2 adrenergic receptor-Gs protein complex.Nature.
(2011) 477:549–55. doi: 10.1038/nature10361
12. Goupil E, Fillion D, Clement S, Luo X, Devost D, Sleno R, et al. Angiotensin
II type I and prostaglandin F2alpha receptors cooperatively modulate
signaling in vascular smooth muscle cells. J Biol Chem. (2015) 290:3137–48.
doi: 10.1074/jbc.M114.631119
13. Sleno R, Devost D, Petrin D, Zhang A, Bourque K, Shinjo Y, et al.
Conformational biosensors reveal allosteric interactions between
heterodimeric AT1 angiotensin and prostaglandin F2alpha receptors. J
Biol Chem. (2017) 292:12139–52. doi: 10.1074/jbc.M117.793877
14. Devost D, Sleno R, Petrin D, Zhang A, Shinjo Y, Okde R, et al. Conformational
profiling of the AT1 angiotensin ii receptor reflects biased agonism, G
protein coupling, and cellular context. J Biol Chem. (2017) 292:5443–56.
doi: 10.1074/jbc.M116.763854
15. Schrage R, Schmitz AL, Gaffal E, Annala S, Kehraus S, Wenzel D, et al. The
experimental power of FR900359 to study Gq-regulated biological processes.
Nat Commun. (2015) 6:10156. doi: 10.1038/ncomms10156
16. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome
engineering using the CRISPR-Cas9 system. Nat Protoc. (2013) 8:2281–308.
doi: 10.1038/nprot.2013.143
17. Namkung Y, Le Gouill C, Lukashova V, Kobayashi H, Hogue M, Khoury E,
et al. Monitoring G protein-coupled receptor and beta-arrestin trafficking
in live cells using enhanced bystander BRET. Nat Commun. (2016) 7:12178.
doi: 10.1038/ncomms12178
18. Sleno R, Petrin D, Devost D, Goupil E, Zhang A, Hebert TE. Designing BRET-
based conformational biosensors for G protein-coupled receptors. Methods.
(2016) 92:11–8. doi: 10.1016/j.ymeth.2015.05.003
19. Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V, et al. Pepducin
targeting the C-X-C chemokine receptor type 4 acts as a biased agonist
favoring activation of the inhibitory G protein. Proc Natl Acad Sci USA. (2013)
110:E5088–5097. doi: 10.1073/pnas.1312515110
20. Zimmerman B, Beautrait A, Aguila B, Charles R, Escher E, Claing A,
et al. Differential beta-arrestin-dependent conformational signaling and
cellular responses revealed by angiotensin analogs. Sci Signal. (2012) 5:ra33.
doi: 10.1126/scisignal.2002522
21. Wrzal PK, Goupil E, Laporte SA, Hebert TE, Zingg HH. Functional
interactions between the oxytocin receptor and the beta2-adrenergic receptor:
implications for ERK1/2 activation in human myometrial cells. Cell Signal.
(2012) 24:333–41. doi: 10.1016/j.cellsig.2011.09.019
22. Petrin D, Robitaille M, Hebert TE. Real-time BRET assays to measure
G protein/effector interactions. Methods Mol Biol. (2011) 756:245–61.
doi: 10.1007/978-1-61779-160-4_13
23. Bourque K, Petrin D, Sleno R, Devost D, Zhang A, Hebert TE.
Distinct conformational dynamics of three G protein-coupled receptors
measured using FlAsH-BRET biosensors. Front Endocrinol. (2017) 8:61.
doi: 10.3389/fendo.2017.00061
24. Leonard AP, Appleton KM, Luttrell LM, Peterson YK. A high-content, live-
cell, and real-time approach to the quantitation of ligand-induced beta-
Arrestin2 and Class A/Class B GPCR mobilization.Microsc Microanal. (2013)
19:150–70. doi: 10.1017/S1431927612014067
25. Goupil E, Wisehart V, Khoury E, Zimmerman B, Jaffal S, Hebert TE,
et al. Biasing the prostaglandin F2alpha receptor responses toward EGFR-
dependent transactivation of MAPK. Mol Endocrinol. (2012) 26:1189–202.
doi: 10.1210/me.2011-1245
26. Paradis JS, Ly S, Blondel-Tepaz E, Galan JA, Beautrait A, Scott MG,
et al. Receptor sequestration in response to beta-arrestin-2 phosphorylation
by ERK1/2 governs steady-state levels of GPCR cell-surface expression.
Proc Natl Acad Sci USA. (2015) 112:E5160–5168. doi: 10.1073/pnas.15088
36112
27. Woodward DF, Jones RL, Narumiya S. International union of basic and
clinical pharmacology. LXXXIII: classification of prostanoid receptors,
Frontiers in Endocrinology | www.frontiersin.org 11 March 2019 | Volume 10 | Article 162
Fillion et al. β-Arrestin Recruitment to FP/AT1R Heterodimer
updating 15 years of progress. Pharmacol Rev. (2011) 63:471–538.
doi: 10.1124/pr.110.003517
28. Griffin BW, Klimko P, Crider JY, Sharif NA. (1999). AL-8810: a novel
prostaglandin F2 alpha analog with selective antagonist effects at the
prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 290:1278–84.
29. Gurevich VV, Gurevich EV. Arrestins: critical players in trafficking
of many GPCRs. Prog Mol Biol Transl Sci. (2015) 132:1–14.
doi: 10.1016/bs.pmbts.2015.02.010
30. Mores KL, Cassell RJ, van Rijn RM. Arrestin recruitment and signaling
by G protein-coupled receptor heteromers. Neuropharmacology. (2018).
doi: 10.1016/j.neuropharm.2018.11.010
31. Luttrell LM, Wang J, Plouffe B, Smith JS, Yamani L, Kaur S, et al. Manifold
roles of beta-arrestins in GPCR signaling elucidated with siRNA and
CRISPR/Cas9. Sci Signal. (2018) 11:eaat7650. doi: 10.1126/scisignal.aat7650
32. Gibson AE, Noel RJ, Herlihy JT, Ward WF. Phenylarsine oxide inhibition
of endocytosis: effects on asialofetuin internalization. Am J Physiol. (1989)
257:C182–184. doi: 10.1152/ajpcell.1989.257.2.C182
33. Jonas KC, Fanelli F, Huhtaniemi IT, Hanyaloglu AC. Single molecule analysis
of functionally asymmetric G protein-coupled receptor (GPCR) oligomers
reveals diverse spatial and structural assemblies. J Biol Chem. (2015) 290:3875–
92. doi: 10.1074/jbc.M114.622498
34. Mishra AK, Gragg M, Stoneman MR, Biener G, Oliver JA, Miszta P, et al.
Quaternary structures of opsin in live cells revealed by FRET spectrometry.
Biochem J. (2016) 473:3819–36. doi: 10.1042/BCJ20160422
35. Damian M, Martin A, Mesnier D, Pin JP, Baneres JL. Asymmetric
conformational changes in a GPCR dimer controlled by G proteins. EMBO
J. (2006) 25:5693–702. doi: 10.1038/sj.emboj.7601449
36. Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1
receptor research: focus on inverse agonism, receptor dimerization and biased
agonism. Pharmacol Res. (2017) 123:40–50. doi: 10.1016/j.phrs.2017.06.013
37. Dai S, Hall DD, Hell JW. Supramolecular assemblies and localized
regulation of voltage-gated ion channels. Physiol Rev. (2009) 89:411–52.
doi: 10.1152/physrev.00029.2007
38. Siddiquee K, Hampton J, McAnally D, May L, Smith L. The apelin receptor
inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J
Pharmacol. (2013) 168:1104–17. doi: 10.1111/j.1476-5381.2012.02192.x
39. Bellot M, Galandrin S, Boularan C, Matthies HJ, Despas F, Denis C, et al. Dual
agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-
PKA signaling. Nat Chem Biol. (2015) 11:271–9. doi: 10.1038/nchembio.1766
40. Haspula D, Clark MA. MAPK activation patterns of AT1R and CB1R
in SHR versus Wistar astrocytes: evidence of CB1R hypofunction
and crosstalk between AT1R and CB1R. Cell Signal. (2017) 40:81–90.
doi: 10.1016/j.cellsig.2017.09.002
41. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of β-
adrenergic and angiotensin II receptors by a single antagonist: a functional
role for receptor-receptor interaction in vivo. Circulation. (2003) 108:1611–8.
doi: 10.1161/01.CIR.0000092166.30360.78
42. Toth AD, Gyombolai P, Szalai B, Varnai P, Turu G, Hunyady L.
Angiotensin type 1A receptor regulates β-arrestin binding of the β2-
adrenergic receptor via heterodimerization. Mol Cell Endocrinol. (2017)
442:113–24. doi: 10.1016/j.mce.2016.11.027
43. Borghi C, Rossi F. Role of the renin-angiotensin-aldosterone system
and its pharmacological inhibitors in cardiovascular diseases: complex
and critical issues. High Blood Press Cardiovasc Prev. (2015) 22:429–44.
doi: 10.1007/s40292-015-0120-5
44. Yu Y, Lucitt MB, Stubbe J, Cheng Y, Friis UG, Hansen PB, et al. Prostaglandin
F2α elevates blood pressure and promotes atherosclerosis. Proc Natl Acad Sci
USA. (2009) 106:7985–90. doi: 10.1073/pnas.0811834106
45. Jenkin G. Oxytocin and prostaglandin interactions in pregnancy and at
parturition. J Rep Fertil Suppl. (1992) 45:97–111.
46. Mejia R, Waite C, Ascoli M. Activation of Gq/11 in the mouse corpus
luteum is required for parturition. Mol Endocrinol. (2015) 29:238–46.
doi: 10.1210/me.2014-1324
47. Yamaleyeva LM, Neves LA, Coveleskie K, Diz DI, Gallagher PE, Brosnihan
KB. AT1, AT2, and AT(1-7) receptor expression in the uteroplacental unit of
normotensive and hypertensive rats during early and late pregnancy. Placenta.
(2013) 34:497–502. doi: 10.1016/j.placenta.2013.03.008
48. Cox BE, Ipson MA, Shaul PW, Kamm KE, Rosenfeld CR. Myometrial
angiotensin II receptor subtypes change during ovine pregnancy. J Clin Invest.
(1993) 92:2240–8. doi: 10.1172/JCI116827
49. Bird IM, Zheng J, Cale JM, Magness RR. Pregnancy induces an increase in
angiotensin II type-1 receptor expression in uterine but not systemic artery
endothelium. Endocrinology. (1997) 138:490–8. doi: 10.1210/endo.138.1.4879
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Fillion, Devost, Sleno, Inoue and Hébert. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Endocrinology | www.frontiersin.org 12 March 2019 | Volume 10 | Article 162
